In the future, targeting the tumor microenvironment, such as by interrupting the immune cells (e.g., myeloid-derived suppressor cells) and cytokines [e.g., interleukin (IL)-6, IL-8] as well as the immune checkpoints [programmed cell death protein 1/programmed cell death ligand 1 (PD1/PDL1)], may provide additional new tools for immunological targeting of cancer stem cells [86]. This evidence concerns the gene IL6 and cancer.